Study for Evaluation of Safety and Efficacy of Pulmonary Artery Denervation to TreatCombined Post- and Pre- Capillary Pulmonary Hypertension Associated with Chronic Heart Failure: a Pilot Study
The goal of this pilot study is to evaluate the safety and efficacy of pulmonary artery denervation (PADN) in Combined Post- and Pre- Capillary Pulmonary Hypertension Associated with Chronic Heart Failure.
Participants who have received guideline-directed medical therapy (GDMT) according to 2022 AHA/ACC Guidelines for Heart Failure (HF) and have been clinically stable for at least 1 month, will be treated with PADN and followed for 1 year.
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Single-use Ring-shaped Pulmonary Artery Radiofrequency (RF) Ablation Catheter and Pulmonary Artery RF Ablation Generator for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension associate with left heart disease (PH-LHD) by right heart catheterization.
A Randomised, Single-blind, Sham Operation-controlled Study to Evaluate the Safety and Efficacy of the Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension
The objective of this randomized control trial is to gain clinical insight on the use of pulmonary artery denervation (PADN) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of PADN for the treatment of PAH.
100 项与 无锡帕母医疗技术有限公司 相关的临床结果
0 项与 无锡帕母医疗技术有限公司 相关的专利(医药)
近日,帕母医疗宣布Krishna Sudhir博士正式加入帕母医疗科学顾问委员会(Scientific Advisory Board)。Krishna Sudhir博士将为帕母医疗的技术平台和研发管线布局提供科学指导,协力推动创新技术孵化及产品国际化进程,助力中国原创技术走向全球。
Krishna Sudhir博士是心血管领域的杰出专家,目前担任斯坦福大学心脏血管技术中心医学顾问教授。他曾任雅培心血管(Abbott Vascular)医学事务部全球副总裁,其在医学领域的技术研发、医学探索、商业化战略思维等方面拥有丰富的国际化领导经验。
在此前,他先后进入加州大学旧金山分校、阿尔弗雷德心脏中心和贝克心脏和糖尿病研究所,专注于心脏疾病领域研究;后在Pharmacyclics、Millennium和diaDexus等多家医药公司负责临床研究和医学事务工作;后加入强生公司(Johnson & Johnson),担任Macroflux Internal Venture的执行董事。
Krishna Sudhir博士先后在Madras Medical College获得医学博士学位、Monash University获得哲学博士学位,卓越的学术成就让他获得无数荣誉,同时他还拥有澳大利亚皇家医学院院士、美国心脏病学会和心脏血管造影与介入学会会员等多重身份。
100 项与 无锡帕母医疗技术有限公司 相关的药物交易
100 项与 无锡帕母医疗技术有限公司 相关的转化医学